Corteria Pharmaceuticals, a Paris, France-based biopharmaceutical company specialized in the development of therapies for unaddressed heart failure subpopulations, raised €65M in Series A funding.
The round was led by OrbiMed and Jeito Capital, with participation from existing seed investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital. As a result, Erez Chimovits from OrbiMed and Andreas Wallnoefer from Jeito Capital will join the board of Directors of Corteria.
The company intends to use the funds to advance its cardiovascular pipeline into the clinic.
Founded in 2021 by Philip Janiak and Marie-Laure Ozoux, Corteria Pharmaceuticals is advancing drugs in heart failure subpopulations.
Since foundation, the company’s pipeline has expanded and now includes three first-in-class therapies that are highly differentiated as they produce multi-organ benefits, acting on the kidneys, the heart, and the vessels:
- A once daily subcutaneous CRF2 agonist for the treatment of Worsening Heart Failure
- A once monthly subcutaneous CRF2 agonist for the treatment of Right Heart Failure
- An AVP (arginine vasopressin) neutralizing monoclonal antibody for the treatment of Acute Heart Failure with Hyponatremia
The lead asset for Worsening Heart Failure is expected to enter the clinic in early 2024.
FinSMEs
07/09/2023